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Abstract 
Background: The Probiotics in Prevention of Allergy among Children in Trondheim (ProPACT) study, a randomised, 
placebo controlled trial, demonstrated that maternal supplementation with probiotic milk reduced the incidence of 
atopic dermatitis (AD) in infancy. The mechanisms behind this effect are incompletely understood and breast milk 
cytokines have been postulated as possible mediating factors. In this study we aimed to assess whether breast milk 
TLSP and TGF-β are affected by a maternal probiotic supplementation regime, and their contribution to the preven-
tive effect of this regime on AD in the offspring.
Methods: TSLP and TGF-β isoforms (TGF-β1, TGF-β2 and TGF-β3) were measured using ELISA and multiplex assays, 
respectively, in breast milk samples collected at 10 days and 3 months postpartum from women participating in the 
ProPACT trial (n = 259). The natural indirect and direct effects of maternal probiotics on AD, due to changes in breast 
milk cytokines, were estimated using causal mediation techniques.
Results: Probiotic supplementation tend to lead to high levels of breast milk TSLP at 10 days postpartum (p = 0.062), 
but this change did not contribute to the prevention of AD according to the mediation analysis. Probiotics had no 
apparent effect on TSLP at 3 months or TGF-βs at either time points. Thus, these are unlikely to be mediators of the 
effect of maternal probiotics on AD in offspring.
Conclusions: Whilst maternal probiotic supplementation resulted in higher breast milk concentrations of TLSP at 
10 days postpartum, this does not appear to be a mechanism for prevention of AD by maternal probiotics.
Trial registration The original trial protocol is registered in ClinicalTrials.gov (identifier NCT00159523)
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Background
Perinatal supplementation with probiotics has been 
shown to reduce the incidence of atopic dermatitis 
(AD) in infancy [1, 2]. Our own study, the Probiotics in 
the Prevention of Allergies among Children in Trond-
heim (ProPACT) trial, demonstrated a 40  % reduction 
in the development of AD following maternal probiotic 
supplementation [3]. However, the biological mecha-
nisms behind this effect are incompletely understood. 
Using samples taken during the ProPACT trial, we have 
previously reported that the maternal intestinal micro-
biota is modified by probiotic supplementation, and that 
children born to mothers who received the probiotics 
have a higher abundance of Lactobacillus rhamnosus GG 
(LGG) which persists up until 3 months of age [4]. Whilst 
the transfer of such probiotic bacteria from mother to 
child may prevent AD, alterations in various compo-





*Correspondence:  melanie.simpson@ntnu.no 
4 Det medisinske fakultet, Instiutt for samfunnsmedisin, MTFS, NTNU, 
Postboks 8905, 7491 Trondheim, Norway
Full list of author information is available at the end of the article
Page 2 of 9Simpson et al. Clin Transl Allergy  (2016) 6:27 
In addition to being a source of nutrition and hydra-
tion for newborn infants, breast milk contains a num-
ber of immunologically active cells and molecules, such 
as immunoglobulins, lactoferrins, growth factors and 
cytokines [5]. Among the cytokines found in breast milk 
are thymic stromal lymphopoietin (TSLP) and the trans-
forming growth factor-β (TGF-β) cytokines. TSLP has 
been implicated in the establishment and maintenance of 
T helper type 2 (Th2) responses, and thus also in defence 
against helminthic infections and in the pathogenesis of 
allergy related diseases [6]. Genetic variants of TSLP have 
been associated with AD and asthma [7] and high levels 
of epidermal TSLP precede the clinical presentation of 
childhood AD [8], suggesting that TSLP may be particu-
larly important in the establishment of AD. Other stud-
ies have demonstrated that TSLP activates skin dendritic 
cells promoting a Th2 response and interacts directly with 
skin-homing Th2 cells to enhance  interleukin-4 (IL-4) 
production which is thought to contribute to the main-
tenance of inflammation in chronic AD [9, 10]. Consist-
ent with these studies, higher concentrations of TSLP 
have been reported in both acute and chronic AD lesions 
[6]. Murine models have shown that over-expression of 
TSLP in keratinocytes induces an AD-like skin disease 
and can predispose to allergic airway inflammation after 
intranasal challenge. Thus, TSLP may also be involved in 
the progression to other allergy related diseases, a pro-
cess often referred to as the atopic march [6]. However, 
the biological effects of breast milk TSLP for the mother 
and child are unknown [11], and this cytokine is previ-
ously unstudied within the context of maternal probiotic 
supplementation. Neither has the effect of maternal atopy 
on breast milk TSLP been investigated, nor the associa-
tion between breast milk TSLP and the development of 
AD. In contrast to TSLP, the human isoforms of TGF-β 
(TGF-β1, TGF-β2 and TGF-β3) are primarily implicated in 
inhibition of allergic inflammation through a wide range 
of immunoregulatory effects [12]. All three isoforms of 
TGF-β are found in breast milk. Studies investigating the 
effect of probiotic supplementation on breast milk TGF-β 
concentrations and or their association with later allergy 
related disease in offspring, have produced conflicting 
results [13–18].
Both TSLP and TGF-βs appear to have important 
roles in acute and chronic phases of allergy related dis-
ease, which makes them interesting as potential media-
tors of this preventive effect. The aims of the current 
study were to: (a) determine if perinatal maternal probi-
otic supplementation alters the concentration of TLSP, 
TGF-β1, TGF-β2 or TGF-β3 in breast milk at 10 days and 
3 months postpartum and (b) investigate if these breast 
milk cytokines contribute to the preventative effect of 
maternal probiotic supplementation on the development 
of AD at 2  years of age through causal mediation 
analysis.
Methods
Participant recruitment and sample collection
The ProPACT trial enrolled 415 pregnant women who 
were randomised to receive 250 mL per day of probiotic 
or placebo milk from 36 weeks gestation until 3 months 
postpartum [3]. The probiotic milk contained 5  ×  1010 
colony-forming units (CFUs) of Lactobacillus rhamno-
sus GG (LGG) and Bifidobacterium animalis subsp. lactis 
Bb-12 (Bb-12) and 5 ×  109 CFU of L. acidophilus La-5 
(La-5) per serving. The placebo was a fermented skim 
milk, pasteurised after fermentation and contained no 
probiotic bacteria. Participants completed lifestyle ques-
tionnaires at baseline (~30–36 weeks gestation), 6 weeks, 
1 and 2  years postpartum and child health question-
naires at 1 and 2 years of age. The outcome of interest in 
the current study was the development of AD by 2 years 
of age as diagnosed by a paediatrician using the United 
Kingdom (UK) Working Party Diagnostic criteria [19]. 
Detailed descriptions of the ProPACT study design and 
clinical outcomes have been published previously [3, 20].
Breast milk samples were collected into a sterile con-
tainer at 10  days and 3  months postpartum and stored 
in the participant’s home freezer until transported to 
the laboratory in Styrofoam containers to prevent thaw-
ing. Samples were subsequently stored at −80  °C until 
analysis. All mother-infant pairs that attended the 2 year 
clinical follow-up and submitted at least one breast milk 
sample were eligible for inclusion in this study.
Cytokine quantification
Breast milk samples were thawed and centrifuged 
(16,100g, 10  min, 4  °C) to remove the lipids, cells and 
debris. The aqueous portion was used for subsequent 
cytokine quantification. TSLP concentrations were meas-
ured using a human TLSP ELISA kit (R&D Systems, 
Minneapolis, USA) according to the manufacturer’s 
instructions. The standards and an internal control were 
conducted in triplicate. The intra-assay coefficient of var-
iation (CV) was <13.5 % and inter-assay CV was 22 %. A 
large proportion of the samples had TSLP concentrations 
outside of the detection limits of the assay, both above 
and below. We have therefore categorised the TSLP con-
centrations into the following 4 categories: below detec-
tion, low detectable, high detectable and above detection. 
The internal control sample was chosen as the cut-off 
between the low and high detectable categories, because 
it was approximately the median concentration and max-
imised the inter-assay comparability. For the purpose of 
mediation analysis TSLP was categorised into a binary 
variable above and below the internal control.
Page 3 of 9Simpson et al. Clin Transl Allergy  (2016) 6:27 
TGF beta concentrations were measured using a mul-
tiplex assay (Bio-Plex Pro TGF-β assay, Bio-Rad Labo-
ratories, Oslo, Norway) following the manufacturer’s 
instructions which included an actvation step. Prior to 
analysis, 100  µL of the aqueous portion of breast milk 
was activated using 20  µL 1  N HCl for 10  min at room 
temperature, followed by neutralisation using 20 µL 1 N 
NaOH with 0.5 M HEPES. The standard and two internal 
control samples were conducted in duplicate. Concentra-
tions were calculated using standard curves and scaled by 
1.4 due to dilution in the activation-neutralisation pro-
cess. The intra-assay CVs were <13.6, <13.4 and <14.6 % 
and the inter-assay CV were <9.9, <5.9 and <14.3  % for 
TGF-β1, TGF-β2 and TGF-β3, respectively.
Statistical analysis
As described, TSLP concentrations were categorised 
into a four groups, and the effect of probiotics was 
assessed using ordinal logistic regression. The distri-
butions of TGF-βs were right-skewed and concentra-
tions are reported as medians and interquartile ranges. 
Wilcoxon matched-pairs signed-rank test was used to 
compare the concentration at 10 days and 3 months for 
the 243 women with TGF-β isoforms measured at both 
time points. The effect of probiotic supplementation on 
TGF-β concentrations was assessed using linear regres-
sion on log-transformed concentrations. Maternal atopy, 
maternal smoking during the first year of life and the 
presence of older siblings were considered to be poten-
tial moderators of the effect of probiotics on cytokine 
concentrations. The effect of probiotics on the breast 
milk cytokines were therefore also assessed in alternate 
regression models which included these covariates.
Causal mediation analysis was performed using the user 
written command, paramed, for breast milk cytokines 
which were found to be altered by probiotic supplemen-
tation. This analysis estimated the natural indirect effect 
(NIE) and natural direct effect (NDE) of maternal pro-
biotic supplementation on the development of AD in 
offspring, mediated through breast milk cytokine concen-
trations, using counterfactual definitions of these effects 
and a log-binomial regression model for AD, given AD 
is not rare [21–23]. In this study, the NIE represents the 
effect of the probiotic regime on the development of AD 
which can be attributed to its effect on the breast milk 
cytokine. The NDE represents an estimation of what the 
relative risk (RR) of developing AD after maternal probi-
otic supplementation would have been, had there been no 
effect on the concentration of the breast milk cytokine. 
The paramed command does not currently support mod-
els with ordinal mediator variables and TSLP concentra-
tions were therefore dichotomised for mediation analysis. 
Whilst the randomised design ensures that the effect of 
probiotics on breast milk cytokines and on AD can be 
estimated without confounding, the relationship between 
cytokine concentration in breast milk and the develop-
ment of AD is not randomised. As such, the estimation of 
NIE and NDE may be confounded by factors which influ-
ence both breast milk cytokine concentrations and the 
risk of developing AD in offspring. The previously men-
tioned covariates were therefore included in the media-
tion analysis as potential confounders of the relationship 
between breast milk composition and AD. All statistical 
analyses were performed using Stata IC release 13 (Stata-
Corp, College Station, Texas).
Results
Participants
Two hundred and fifty-nine mother-infant pairs were 
included in this analysis, 129 from the probiotic group 
and 130 from the placebo group (Fig. 1). This subgroup of 
participants is representative of the original study popu-
lation with respect to distribution of baseline characteris-
tics and allergy related disease outcomes [3]. Compliance 
was high and equivalent in both groups. At baseline, the 
probiotic group contained more male children and at 
2 years of age there were fewer cases of AD (Table 1). In 
terms of maternal characteristics which have been pre-
viously suggested to influence breast milk cytokine con-
centration, fewer women in the probiotic group had a 
personal history of atopy (Table 1). There were also fewer 
women smoking at 6 weeks postpartum in the probiotic 
group, although the overall prevalence of smoking was 
very low (8 of 259, 3.2 %). 
Thymic stromal lymphopoietin
A greater proportion of breast milk samples taken 
10  days postpartum had high concentrations of TLSP 
compared with the samples taken at 3  months (Fig.  2). 
The concentration of TSLP was below the lower limit 
of detection (31.3 pg/mL) in 18.9 % and 26.7 % of sam-
ples collected at 10  day and 3  months postpartum, 
respectively, and above the limit of detection (2000  pg/
mL) in 25.6 % and 17.3 %, respectively. Ordered logistic 
regression revealed a borderline non-significant effect 
of probiotics on TLSP concentration (OR 1.55 95  % CI 
0.98–2.45, p = 0.062) at 10 days postpartum which was 
not sustained at 3 months postpartum (OR 1.35 95 % CI 
0.84–2.16, p  =  0.219). This effect was not significantly 
altered when adjusting individually or in combination for 
maternal atopy, maternal smoking or older siblings. The 
effect of probiotics on breast milk TSLP concentration at 
10 days postpartum was marginally enhanced when con-
sidering only women compliant with the study protocol 
(n =  209, OR 1.74, 95  % CI 1.06–2.84, p =  0.028). We 
did not find evidence of an association between maternal 
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Randomised 
(n = 415) 
Allocated to probiotic group (n=211) 
Received allocated intervention (n=210)
Allocated to probiotic group (n=204) 
Received allocated intervention (n=204)
Excluded from current analysis:  
No clinical follow-up (n = 72) 
No breast milk samples available despite 
clinical follow-up (n = 9) 
Excluded from current analysis:  
No clinical follow-up (n = 64) 
No breast milk samples available despite 
clinical follow-up (n = 10) 
Included (n=129a) 
Complete covariatesb (n = 129)  
 Included (n=130a) 
Complete covariatesb (n = 129) 
Fig. 1 Flow diagram of participants in the ProPACT study and cytokine analysis of breast milk samples. aThe provided values represent the number 
of eligible women who had provided at least one breast milk sample. The precise number of samples analysed for each cytokine at each time point 
varies and is provided in association with the relevant results. bComplete covariates additionally required information on maternal atopy, maternal 
smoking and the presence of older siblings
Table 1 Baseline characteristics of participating families and allergy related disease in the children at 2 years
a Maternal smoking reported during pregnancy, 6 weeks or 12 months postpartum; b Compliance with the study protocol was defined by consumption of the study 
milk on at least 50 % of days from 36 weeks gestation to 12 postpartum, no consumption of other products with probiotics and at least partial breastfeeding until 
3 months postpartum; c p-value calculated using χ2-test, except for allergic rhinoconjunctivits where a Fisher’s exact p value is reported; d Allergic sensitisation defined 
as positive skin prick test (wheal ≥ 3 mm) and or positive sIgE (≥ 0.35 kUL−1)
Characteristics Probiotic Placebo
n n
Age, mother, yrs mean (SD) 129 30.5 (3.9) 130 30.3 (4.1)
Sex (male), child, n (%) 129 67 (51.9) 130 53 (40.8)
Siblings, n (%) 129 60 (46.5) 130 54 (41.5)
Atopy in family, n (%) 129 91 (70.5) 130 96 (73.9)
Maternal atopy, n (%) 129 58 (45.0) 129 68 (52.7)
Maternal smokinga, n (%) 129 9 (7.0) 130 11 (8.5)
Compliantb, n(%) 125 113 (90.4) 128 115 (89.8)
Allergy related disease at 2 years n n (%) n n (%) p-valuec
Atopic dermatitis, n (%) 129 29 (22.5) 130 45 (34.6) 0.031
Asthma, n (%) 129 7 (5.4) 130 12 (9.2) 0.240
Allergic rhinoconjunctivits, n (%) 125 1 (0.8) 129 0 (0.0) 0.492
Sensitisationd, n (%) 122 19 (15.6) 124 15 (12.1) 0.429
Page 5 of 9Simpson et al. Clin Transl Allergy  (2016) 6:27 
atopy, maternal smoking or the presence of older siblings 
and TSLP in univariate analysis.
Transforming growth factor β
All three TGF-β isoforms were detectable in all breast 
milk samples, with the exception of one sample col-
lected at 3  months postpartum which had undetectable 
TGF-β3. Similar to TSLP, the concentrations of TGF-β1, 
TGF-β2 and TGF-β3 were higher at 10 days postpartum 
compared with 3  months postpartum (Fig.  3). Probiotic 
supplementation had no observed effect on the concen-
tration of any of the TGF-β subtypes at either time point 
(Table 2). This lack of effect was not substantially altered 
when adjusting for potential moderators or when consid-
ering the subgroup of women compliant with the study 
protocol (n = 219–224).
Breast milk cytokines as potential mediators 
of preventative effect on atopic dermatitis
For the purposes of mediation analysis, TSLP con-
centrations at 10  days were dichotomised. Consistent 
with the ordinal logistic regression analysis, standard 
logistic regression on the dichotomised TSLP values 
also suggested that perinatal probiotic supplementa-
tion increased the odds of a high TSLP concentration 
at 10  days (OR 1.72, 95  % CI 1.03–2.87, p  =  0.039). 
However, mediation analysis suggested that the effect 
of probiotics on TSLP did not result in a significant 
reduction, or increase, in the risk of developing AD 
[RRNIE 1.04 (95  % CI 0.94–1.15, p  =  0.45)], Fig.  4). 
Breast milk TSLP concentrations at 3  months post-
partum and the TGF-β cytokines at both 10  days and 
3  months postpartum were not demonstrably affected 
by probiotic supplementation, indicating that changes 
in these breast milk cytokines are unlikely to be respon-
sible for the reduced risk of developing AD observed 
after maternal probiotic supplementation. As such, no 
estimation of NIE and NDE was conducted for these. 
Furthermore, none of the cytokines, including TSLP at 
10 days, were found to be significantly associated with 
the development of AD when assessed independently 
of treatment allocation.
Fig. 2 Breast milk TSLP concentrations at 10 days and 3 months in the probiotic and placebo groups. Proportion of breast milk samples with cat-
egorised TSLP concentrations at 10 days and 3 months postpartum in the placebo and probiotic group. Percentages are provided within the bars. 
Overall, higher concentrations of TSLP were measured significantly more often in samples collected at 10 days postpartum (p < 0.001 from ordinal 
logistic regression clustered by individual). Also on subgroup analysis, TSLP concentrations were significantly higher at 10 days in both the probiotic 
group (p < 0.001) and placebo group (p = 0.005)
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Discussion
Thymic stromal lymphopoietin was the only cytokine 
with a tendency to be affected by maternal probiotic 
supplementation, resulting in higher concentrations of 
TSLP at 10  days postpartum. Causal mediation analysis 
indicated that the higher concentrations of TSLP at 
10  days did not appear to contribute to the beneficial 
effect of probiotics on the development of AD in off-
spring. TSLP concentrations at 3  months postpartum 
and TGF-βs at both time points were not affected by 
Fig. 3 Concentrations of TGF-β1, 2 and 3 at 10 days and 3 months. All three isoforms of TGF-β are found at statistically significantly lower levels at 
3 months postpartum compared to 10 days postpartum (p < 0.001 for all isoforms using Mann–Whitney U-test)
Table 2 Breast milk TGF-β concentrations in the probiotic and placebo groups at 10 days and 3 months postpartum
a The upper p-value provided is from the regression analysis of the influence of probiotic ingestion on the log transformed TGF beta concentration by, whilst the 
lower represents the p-value calculated for the effect of treatment allocation after adjusting for maternal atopy, maternal smoking and presence of siblings
Days Treatment pa
Probiotic Placebo
n Median (IQR) (pg/mL) n Median (IQR) (pg/mL)
TGF-β1 10 128 616.9 (407.5–950.4) 127 617.3 (369.7–853.9) 0.34
0.33
90 123 438.5 (308.0–661.1) 124 417.4 (269.3–641.8) 0.27
0.23
TGF-β2 10 128 909.8 (451.6–1653.8) 127 999.4 (519.0–1517.1) 0.90
0.83
90 123 599.6 (311.0–1055.1) 124 532.5 (285.9–1144.2) 0.76
0.69
TGF-β3 10 128 37.8 (25.3–58.7) 127 35.8 (22.9–57.2) 0.25
0.33
90 123 29.9 (21.0–42.7) 123 30.8 (18.8–48.7) 0.95
0.86
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probiotic supplementation. As such, these breast milk 
cytokines are unlikely to be mediators of the beneficial 
effect of probiotics.
This study provides the first report of the influence 
of a maternal probiotic supplementation on breast 
milk TLSP concentrations and investigates its contri-
bution to the prevention of AD. In experimental and 
observational studies, TSLP has been associated with 
promotion of a Th2 and allergic type inflammation, par-
ticularly in the lung and skin [6, 24]. Therefore, the find-
ing that probiotic supplementation increased the breast 
milk TSLP concentrations was contrary to what one 
might have expected. At the same time, high breast milk 
TSLP may not be as detrimental in the intestinal sys-
tem where it is described as having a more regulatory 
function [24, 25]. TSLP released by intestinal epithelial 
cells in response to commensal bacteria has been shown 
to promote tolerogenic properties in dendritic cells 
and macrophages which then produce IL-10 and reti-
noic acid and promote regulatory T helper (Treg) cell 
differentiation [25]. Thus the increased TSLP seen in 
the probiotic group may encourage intestinal immune 
homeostasis, which in turn is theoretically beneficial for 
the development of the neonatal immune system and 
prevention of AD. However, the current data does not 
suggest that breast milk TSLP contributes to the preven-
tative effect of probiotics on AD, nor does it appear to 
be associated with the development of AD. It is unclear 
if the observed lack of mediating effect is due to a loss of 
information and power due to dichotomisation of TSLP 
concentration, TLSP degradation prior to reaching the 
intestines, or a more complex interplay between TSLP, 
the intestinal microbiota and the immune system. Fur-
ther studies are required to confirm these findings.
The major strength of this study is that the ran-
domised placebo controlled, double blind design of the 
ProPACT trial allows an unconfounded assessment of 
the effect of the probiotic regime on the selected breast 
milk cytokines. Furthermore, through causal media-
tion analysis techniques, we are able to estimate if and 
to what extent the prevention of AD is due to changes 
in TSLP. The randomised design also means that two of 
four assumptions required for this mediation analysis 
[21] are automatically satisfied, namely that there is no 
residual confounding of the effect of probiotics supple-
mentation on either AD or breast milk TSLP. The other 
two required assumptions are that there is no unmeas-
ured confounding of the relationship between breast 
milk TSLP and AD and that there is no confounder of 
the mediator-outcome relationship that is affected by 
treatment allocation. Whilst these cannot be excluded, 
we believe we have measured and included all variables 
which are likely to affect both breast milk cytokines and 
AD and that probiotics do not have a strong effect on any 
other confounders of the relationship between these vari-
ables. Another strength of this study is that it is the larg-
est to investigate TSLP concentrations in breast milk and 
the only one to consider infant outcomes and maternal 
atopy status. The only other study to report breast milk 
TSLP concentrations involved 44 women who submitted 
samples at one of two time points [11]. Whilst they also 
found that mature milk tended to have lower TSLP con-
centrations, they reported concentrations which all fell 
within a relatively narrow range. Our results suggest that 
there may be a much greater variability between individ-
uals than this small study managed to detect.
One of the limitations of this study is that the breast 
milk samples were stored between 6 and 8  years before 
analysis. This has potentially affected the measured con-
centrations of TSLP and TGF-βs, as has been previously 
reported for TGF-β1 [26]. However, there was no differ-
ence in the average length of storage between the treat-
ment groups and adjusting for length of storage did not 
significantly alter the estimated effect of probiotic sup-
plementation on any of the measured cytokines (data not 
shown). Another limitation is that the time of sample col-
lection was not standardised with respect to time of day 
and whether fore- or hindmilk was collected. Although 
diurnal and fore-/hindmilk variation has not been specif-
ically investigated for TSLP and TGF-βs, previous studies 
suggest that diurnal variation exists in some breast milk 
cytokines [27] and that the quantity of total protein in 




TSLP (10 days) 




NDE: RR 0.63 (95% CI 0.42 – 0.95, p = 0.03)  
NIE: RR 1.04 (95% CI 0.94 – 1.15, p=0.45) 
Fig. 4 Hypothetical mediation analysis and estimated natural indi-
rect effect (NIE) and natural direct effect (NDE) of maternal probiotic 
supplementation. The NIE is an estimate of the effect of maternal 
probiotic ingestion on the development of AD in offspring mediated 
by increased TSLP levels in breast milk 10 days postpartum. The NDE 
is an estimate of the effect of maternal probiotic ingestion on the 
development of AD not mediated through changes in breast milk 
TSLP concentration 10 days postpartum. This analysis suggests that 
TSLP does not significantly contribute to, or oppose, the preventa-
tive effect of maternal perinatal probiotic supplementation on the 
development of atopic dermatitis
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constant [28]. Whilst these factors may have influenced 
the cytokine concentrations, samples from the probiotic 
and placebo groups are presumably equally affected and 
we do not believe they have significantly affected the 
conclusions of this study. An underlying uncertainty sur-
rounding the measure of breast milk cytokines is another 
limitation to this study. Previous studies of breast milk 
TGF-β and other cytokines have produced widely vary-
ing concentration measurements. Whilst some of this 
variability may be explained by factors such as diurnal 
and fore-/hindmilk variations, ethnicity, maternal atopy 
status and time point postpartum, it is likely that sam-
ple storage, preparation, analysis methods and inter-
laboratory differences play a major role in the measured 
concentrations. As such, it is difficult to compare results 
between studies, particularly when these variables are 
inconsistently reported. In studies comparing two expo-
sure groups, be that probiotic versus placebo or mater-
nal atopy versus no atopy, it is reasonable to assume that 
technical variability between the groups are minimised. 
Thus, comparing groups within each study is valid and 
more generally the relative relationship between these 
groups can be roughly compared across studies.
Five previous studies have reported breast milk TGF-β1 
and or TGF-β2 concentrations from similar randomised 
trials of probiotic supplementation. Each of these stud-
ies found a statistically significant effect of probiotics on 
at least one TGF-β isoform in colostrum samples and no 
effect on concentrations in mature milk. However, they 
provide conflicting evidence as to whether probiotics 
increase [14, 15] or decrease [16–18] colostrum TGF-β 
concentrations. The current study also found no effect of 
probiotic supplementation on TGF-β concentrations in 
mature milk, and provides no evidence to suggest either 
increased or decreased concentrations in breast milk at 
10 days postpartum, a time when the milk is sometimes 
referred as transition milk before colostrum become 
mature milk. In addition to the previously mentioned 
sources of variability, the differing results may also reflect 
a probiotic strain specific effect as none of these studies 
used the same probiotic species in the same dose or com-
binations. In terms of methodological differences, it is 
interesting to note that the two studies reporting reduced 
TGF-β2 after probiotic supplementation also reported the 
manufacturer recommended acid activation of the breast 
milk samples prior to measurement which means that 
the reported concentrations represent the entire pool 
of TGF-β which is naturally found in both a latent and 
active form. On the other hand, all three studies report-
ing higher TGF-β1 or TGF-β2 do not mention this activa-
tion step in their methods. One of these studies, however, 
used an alternate activation procedure which is thought 
to additionally release lipid bound TGF-β [17, 29]. All 
other studies have removed the lipid fraction prior to 
cytokine analysis. If the conflicting reports of positive or 
negative associations with probiotics are a reflection of 
a common effect of probiotics and sample preparation 
method, rather than strain specific effects, it may imply 
that probiotics affect the ratio between active and latent 
TGF-β in breast milk or the proportion of lipid bound 
TGF-β. Other factors are known to affect the propor-
tion of active versus latent TGF-β, for example, mothers 
of premature infants having a higher proportion of latent 
TGF-β [30].
Conclusions
Whilst maternal probiotic supplementation appears to 
result in higher breast milk concentrations of TLSP at 
10  days postpartum, this does not seem contribute to 
the preventative effect of the probiotic regime on the 
development of AD. Probiotics did not significantly alter 
the breast milk concentration of any TGF-β isoforms 
at 10  days or 3  months postpartum. Further studies are 
required to both confirm these findings and investigate 
the other potential mechanism behind the prevention of 
AD in infancy by perinatal probiotic supplementation.
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